Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (5) , 485-488
Abstract
Background: The combination of streptozocin and doxorubicin has been considered the standard palliative chemotherapy regimen in patients with advanced pancreatic endocrine tumors (PETs). However, a recent review failed to confirm high antitumor activity in patients with advanced PETs. Methods: We retrospectively reviewed the records of 16 consecutive patients who received streptozocin and doxorubicin for advanced PETs at Dana Farber/Partners Cancer Care institutions. Baseline patient characteristics, radiographic response to therapy, treatment-related toxicity, progression-free and overall survival were analyzed. Results: One patient demonstrated an objective partial response to therapy (objective response rate [ORR], 6%; 95% confidence interval [CI], 0–18%). Six patients achieved stable disease (38%; 95% CI, 14–62%) and 9 patients demonstrated disease progression on initial restaging (56%; 95% CI, 33–77%). The median progression-free survival and overall survival were 3.9 months (95% CI, 2.8–8.8) and 20.2 months (95% CI, 9.7–37.4), respectively. Conclusions: In this retrospective cohort, the combination of streptozocin and doxorubicin failed to demonstrate substantial antitumor activity in patients with advanced PET. Our findings underscore the need for new therapeutic options in this patient population.Keywords
This publication has 14 references indexed in Scilit:
- ISLET CELL TUMORS OF THE PANCREASSurgical Clinics of North America, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Neuroendocrine gastrointestinal tumoursAnnals of Oncology, 1996
- Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1992
- Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patientsJournal of Internal Medicine, 1990
- TREATMENT OF MALIGNANT ENDOCRINE PANCREATIC TUMOURS WITH HUMAN LEUCOCYTE INTERFERONThe Lancet, 1987
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell CarcinomaNew England Journal of Medicine, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958